Phim Sex Filme Porno PORNO GRÁTIS Filme Porno Phim Sex Ranbaxy Laboratories | Pharmacy News EU

Tag ranbaxy laboratories

Ranbaxy sues US drug regulator for revoking approvals [India Business] [Times of India]

Nov19

NEW DELHI: Drug maker Ranbaxy Laboratories, which is yet to resolve its long pending issues with the US drug regulator, has sued US Food and Drug Administration (US FDA) for revoking approvals granted to the firm for launching low-cost versions of two bestselling medicines Nexium and Valcyte used in treatment of heartburn and for infection […]

Ranbaxy sues FDA for revoking approvals [DNA : Daily News & Analysis (India)]

Nov19

Mumbai: Ranbaxy Laboratories, the company in waiting to be merged with Sun Pharma, has taken a legal recourse against the US drug regulator for revoking the tentative approvals granted for launching the generic versions of AstraZeneca’s heartburn drug Nexium and Roche’s antiviral Valcyte in the US.According to analysts, Ranbaxy could have gained $250 million had […]

Update: CX Partners Invests In Natco Pharma [DealCurry (India)]

Dec3

CX Partners has invested around $18 Mn in Natco Pharma by subscribing to 17 lac equity shares at R638.40 per scrip. The investment would help Natco to augment its manufacturing capacities, broaden its product portfolio and target new markets.Cipher Capital was the sole financial advisor to the company for this transaction.Read More HereRecent deals in […]

Ranbaxy To Exit Vaccine Business

Nov26

Ranbaxy Laboratories is close to make an exit from its Bangalore-based vaccine manufacturing company, Biovel which it acquired in 2010, BS states.Ranbaxy had made an acquisition to foray into the vaccine business but however the company started incurring losses due to which it decided to sell off the business. A loss of R48.5 Cr was […]

US to remain key pharma market for Indian players [DNA : Daily News & Analysis (India)]

Dec31

Come rain or shine, the US will remain the top pick with Indian drugmakers. Currently, players like Ranbaxy Laboratories, Sun Pharma, Glenmark and Lupin derive nearly 28-40% of their revenues from the US. And experts believe this can only rise to 30-45% in coming years.They are of the view that though the US market is […]

RANBAXY ANNOUNCES CONSENT DECREE WITH U.S. FOOD AND DRUG ADMINISTRATION TAKES CORRECTIVE STEPS, COMMITS TO FURTHER MEASURES

Dec21

Gurgaon, India – Ranbaxy Laboratories Ltd. (RLL, NSE: RANBAXY, BSE: 500359) ("Ranbaxy") today announced that it has signed a consent decree with the U.S. Food and Drug Administration ("FDA"). Ranbaxy has committed to further strengthen procedures and policies to ensure data integrity and to comply with current good manufacturing practices. The consent decree is subject […]

Glenmark gets most approvals to sell generic drugs in US [The Economic Times, India]

Mar15

March 15NEW DELHI Glenmark Pharmaceuticals has received the maximum number of approvals to sell lowcost medicines in the US this fiscal, ahead of bigger peers such as Sun Pharma, Ranbaxy Laboratories and Dr Reddy’s, that will support its revenue growth in the coming quarters.In the first eleven months of the fiscal, Glenmark secured nods to […]

Abbott to pay $3.7 billion for unit of India s Piramal

May23

MUMBAI: Abbott Laboratories Inc will pay $3.72 billion to acquire the branded generics business of India s Piramal Healthcare, as global drugmakers look to boost their presence in emerging markets.Takeover speculation had swirled around Piramal, with media reports citing Sanofi-Aventis, Pfizer Inc, and GlaxoSmithKline as possible buyers.Abbott said it will pay $2.12 billion up-front and […]

Abbott to pay $3.7 billion for unit of India s Piramal

May22

MUMBAI: Abbott Laboratories Inc will pay $3.72 billion to acquire the branded generics business of India s Piramal Healthcare, as global drugmakers look to boost their presence in emerging markets.Takeover speculation had swirled around Piramal, with media reports citing Sanofi-Aventis, Pfizer Inc, and GlaxoSmithKline as possible buyers.Abbott said it will pay $2.12 billion up-front and […]

Abbott to pay $3.7 billion for unit of India s Piramal

May21

MUMBAI: Abbott Laboratories Inc will pay $3.72 billion to acquire the branded generics business of India s Piramal Healthcare, as global drugmakers look to boost their presence in emerging markets.Takeover speculation had swirled around Piramal, with media reports citing Sanofi-Aventis, Pfizer Inc, and GlaxoSmithKline as possible buyers.Abbott said it will pay $2.12 billion up-front and […]